35,145 Shares in Kenvue Inc. (NYSE:KVUE) Acquired by Cypress Advisory Group LLC

Cypress Advisory Group LLC bought a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 35,145 shares of the company's stock, valued at approximately $750,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Norges Bank acquired a new stake in shares of Kenvue in the fourth quarter worth about $521,348,000. Franklin Resources Inc. lifted its holdings in Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock worth $912,059,000 after purchasing an additional 16,269,721 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in Kenvue by 3.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares during the last quarter. Finally, Boston Partners grew its holdings in Kenvue by 36.9% during the fourth quarter. Boston Partners now owns 23,595,963 shares of the company's stock valued at $503,145,000 after purchasing an additional 6,366,097 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Price Performance

NYSE KVUE traded up $0.02 during trading on Friday, reaching $23.98. 14,097,083 shares of the company traded hands, compared to its average volume of 17,037,896. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock's 50 day moving average price is $23.09 and its two-hundred day moving average price is $22.51. The company has a market cap of $46.01 billion, a price-to-earnings ratio of 45.25, a P/E/G ratio of 2.62 and a beta of 1.02.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.42%. The ex-dividend date is Wednesday, May 14th. Kenvue's payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on KVUE. Citigroup upped their price objective on shares of Kenvue from $21.00 to $22.00 and gave the stock a "neutral" rating in a report on Monday, April 14th. Piper Sandler raised their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Canaccord Genuity Group lifted their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Redburn Atlantic began coverage on Kenvue in a research note on Thursday, April 10th. They set a "neutral" rating and a $23.50 target price for the company. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Kenvue has a consensus rating of "Hold" and a consensus target price of $24.42.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.